GSK May Exit Treximet Spat But Remain On Hook

Law360, New York (April 28, 2009, 12:00 AM EDT) -- After pulling GlaxoSmithKline PLC into a patent spat over Pozen Inc.'s migraine treatment Treximet, defendant Par Pharmaceutical Inc. has agreed to drop the British pharmaceutical giant from Pozen's infringement suit in light of GSK agreeing to provide discovery and abide by the court's judgment in the consolidated action.

The two drugmakers filed the stipulation and agreed motion to dismiss Monday in the U.S. District Court for the Eastern District of Texas. The suit, filed by Pozen in November, alleged that an abbreviated new drug application that...
To view the full article, register now.